OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On March7, 2019, Ocular Therapeutix,Inc. (the “Company”) announced its financial results for the quarter and year ended December31, 2018. The full text of the press release is furnished as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.
The information in this Current Report on Form8-K, including Exhibit99.1 attached hereto, is furnished to comply with Item 2.02 of Form8-K, and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 2.02 Financial Statements and Exhibits.
(d) Exhibits:
|
99.1 |
Press Release of Ocular Therapeutix,Inc., dated March7, 2019 |
OCULAR THERAPEUTIX, INC Exhibit
EX-99.1 2 a19-5972_1ex99d1.htm EX-99.1 Exhibit 99.1 Ocular Therapeutix Reports Fourth Quarter and Year End 2018 Financial Results and Business Update DEXTENZA® Commercial Launch Planned for Mid-Year 2019 OTX-TP Phase 3 Data Expected in the First Half of 2019 Strengthened Cash Position with Closing of $37.5 Million Financing BEDFORD,…
To view the full exhibit click here
About OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL)
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug. The OTX-TP product candidate incorporates the prostaglandin analog travoprost as an active pharmaceutical ingredient in its punctum plug.